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We investigated the risk of lung cancer in relation to non-steroidal anti-inflammatory drugs (NSAIDs) among 573 cases and 857
sex- and age-matched controls for whom we had information on use of NSAIDs, from a prescription database covering all
pharmacies in Denmark since 1995, and self-reported NSAID use, smoking habits and other potential confounders. Associations
were expressed as odds ratios, assessed by logistic regression in unmatched analyses. After controlling for smoking habits, length of
education and concomitant use of acetaminophen, we found a slightly decreased relative risk of 0.86 (95% confidence intervals,
0.65–1.14) for lung cancer associated with any use of NSAIDs. The risk decreased significantly (P¼0.02) with increasing numbers of
dispensed prescriptions per year during the 1–3 years before the index date with a relative risk of 0.49 (0.28–0.84) among those
with four or more prescriptions per year during this period. Our findings suggest that regular use of NSAIDs is associated with a
slightly or moderately reduced risk for lung cancer.
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Aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) used in relation to lung cancer have been investigated
in at least 20 studies, including four hospital-based case–control
studies (Rosenberg, 1995; Harris et al, 2002; Moysich et al, 2002;
Muscat et al, 2003), fourteen cohort studies (Paganini-Hill et al,
1989; Thun et al, 1993; Schreinemachers and Everson, 1994;
Langman et al, 2000; Akhmedkhanov et al, 2002; Friis et al, 2003;
Holick et al, 2003; Sørensen et al, 2003; Ratnasinghe et al, 2004;
Skriver et al, 2005; Hayes et al, 2006; Herna ´ndez-Diaz and
Rodriguez, 2007; Jacobs et al, 2007; Wall et al, 2007) and three
randomised trials (Peto et al, 1988; Lee et al, 1995; Cook et al,
2007). Significantly decreased risks were observed in three of the
four hospital-based case–control studies (Rosenberg, 1995; Harris
et al, 2002; Moysich et al, 2002), although all were based on self-
reported drug use after diagnosis of cancer, raising the possibility
of recall bias. Of the remaining studies in which drug details were
obtained before diagnosis, only three found significant inverse
associations, two (but with overlapping data) with regular aspirin
use (Schreinemachers and Everson, 1994; Ratnasinghe et al, 2004)
and a third with other NSAID use (Herna ´ndez-Diaz and Rodriguez,
2007). The remaining studies, including the three low-dose aspirin
randomised trials (Peto et al, 1988; Lee et al, 1995; Cook et al,
2007) and a Danish cohort study that we previously reported
(Skriver et al, 2005), revealed a modest, nonsignificantly decreased
risk, no appreciable effect or an increased risk, respectively. The
observational studies relied either on self-reported use of NSAIDs
or did not control sufficiently for smoking habits.
We examined the association between use of NSAIDs and lung
cancer risk based on pooling of data from two studies. We used
self-reported information on drug use as well as a continuously
updated prescription database covering all pharmacies in
Denmark since 1995 (Gaist et al, 1997), supplemented by self-
reported smoking habits.
MATERIALS AND METHODS
Northern Jutland case–control study
For this study, we recruited patients who had been referred to one
of four regional pulmonary centres in the northern part of Jutland
during 2002–2005 for a broncho-mediastinoscopic examination
because of an abnormal or suspect finding on a chest radiograph.
We invited a total of 546 persons, of whom 416 (76%) agreed to
participate. On the date of arrival of the patient at the outpatient
clinic, defined as the index date, the study nurse conducted a
structured face-to-face interview before a broncho-mediastino-
scopy was undertaken. In addition to personal data, which
included the personal identification number, the patient was
asked about use of NSAIDs and acetaminophen, details of current
and past smoking habits and occupational training. Of the 416
patients recruited, 165 (99 men and 66 women) were subsequently
diagnosed with a biopsy-confirmed lung cancer; the remaining 251
patients (60%) were considered to have benign lung disease or an
inert lung lesion and were accordingly excluded from study. We
excluded a further 20 of the 165 patients with lung cancer who
were listed in the Danish National Cancer Registry with a previous
malignancy and one who was under the age of 40 years at the
time of diagnosis, leaving 144 patients for the combined analysis.
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northern Jutland, frequency matched on sex and age on the index
date to the lung cancer patients. Of these, 449 (42%) agreed to
participate and completed the same face-to-face interview as that
used for the cases, but in their homes. Linkage to the files of the
Cancer Registry showed that 21 of these persons had had a cancer
before the index date and they were excluded, leaving 428 controls
for analysis.
Nested case–control study
This study is nested within the Danish Diet, Cancer and Health
prospective cohort study described in detail elsewhere (Tjønneland
et al, 1991, 2004). It was established by the Danish Cancer Society
in 1993–1997, when 160725 persons (80996 men and 79729
women) aged 50–64 years, resident in Copenhagen or Aarhus (the
two largest cities in Denmark) and born in Denmark, were invited
to participate; of these, 57052 (35.5%) agreed to participate.
A mailed questionnaire requested detailed information on current
use of analgesics, current and past smoking habits and occupa-
tional training. Record linkage to the files of the Danish National
Cancer Registry showed that 545 participants had been diagnosed
with cancer before enrolment; these were excluded. Of the
remaining 56511, 429 (228 men and 201 women), diagnosed with
lung cancer between the day of enrolment and 2003, formed the
case group. For each case, we used random incidence density
sampling to select one control subject matched to the case on sex
and age, yielding a control group of 228 men and 201 women. The
date of diagnosis of cases was defined as the index date.
Non-steroidal anti-inflammatory drugs and
acetaminophen data
To assess use of aspirin, other NSAIDs and acetaminophen among
cases and controls in these two studies, we combined self-reported
information from the questionnaire with information from a
national prescription database (Danish Registry of Medical
Product Statistics) at the Danish Medicines Agency (Gaist et al,
1997). The questionnaire included questions on use of specified
pain-relieving pills (aspirin, other NSAIDs, acetaminophen) and
frequency of use. The database holds records of all drug
prescriptions dispensed at all pharmacies in Denmark since 1
January 1995, including the customer’s personal number, type and
amount of drug prescribed according to the Anatomical Ther-
apeutic Chemical (ATC) classification system (Capella ´, 1993) and
date of dispensing. Indications for use and the recommended
dosing schedule are not included.
For each of the 573 (144þ429) cases and the 857 (428þ429)
controls, we identified all prescriptions for aspirin (ATC codes:
B01AC06, N02BA01, N02BA51), other NSAIDs (ATC group: M01A)
and acetaminophen (N02BE01) filed between 1995 to 2005. In
Denmark, NSAIDs other than aspirin are available only by
prescription, except for low-dose ibuprofen (200mg per tablet),
which is available over the counter (OTC) and accounts for
approximately 14% of the total NSAID use (Mellemkjær et al,
2002). Aspirin and acetaminophen can be obtained OTC but
are often prescribed for long-term use; a substantial proportion of
prescribed aspirin is low dose for secondary prevention of
cardiovascular disease, generally under the control of a physician.
Statistical analysis
We estimated lung cancer risk among subjects who had reported
or were registered as having any use of NSAIDs relative to that
in subjects with no such use. Self-reported use of NSAIDs and
acetaminophen was defined as use approximately 1–5 years prior
to the index date in the northern Jutland case–control study and
as intake during the year before the base line interview in the
nested case–control study. This implies that slightly different
windows for self-reported use were, that is, 2002–2005 in the
Northern Jutland case–control study and 1993–1997 in the nested
case–control study. Prescribed use in both studies was defined as
any use of NSAIDs or acetaminophen 1 year or more before the
index date. A lag time of 12 months from the index date was to
avoid registrations of mild analgesics given to treat early
symptoms of lung cancer. As the prospective Diet, Cancer and
Health cohort study was initiated in December 1993 and the
prescription database on 1 January 1995, no data were available on
prescribed NSAIDs for lung cancer cases diagnosed between these
dates; accordingly, they were excluded from analyses based on
personal prescriptions. Associations were expressed as odds ratios
(ORs), assessed by logistic regression in unmatched analyses,
in which the matching criteria (year of birth, sex and study) were
included as covariates with 95% confidence intervals (95% CI).
Non-steroidal anti-inflammatory drug-specific risk estimates were
adjusted for smoking habits, occupational training (unskilled
worker; skilled worker; bachelor; a master’s degree or higher)
and concomitant use of acetaminophen. These analyses were
conducted on the combined study data as well as separately on the
two contributing studies. Risk associated with self-reported use
was estimated separately by frequency (never, ever, monthly,
weekly, daily) and by prescribed use, being the average number
of prescriptions per year in the 1–3 years before the index date
(0.5–2, 2–3, X4), the lowest being 0.5, equivalent to at least one in
a 2-year period. The statistical analyses were performed in SAS 9.1.
Meta-analysis of previously published data
We combined information from all published studies of lung
cancer in relation to aspirin and non-aspirin (or unspecified)
NSAID use providing ORs, standardised mortality ratios, or other
measures of risk in users relative to non-users. Where relative risks
were presented only among subsets of users and not overall, we
utilised the data for the consumers with the heaviest intake. Since
multiple types of study design were used, for the meta-analysis, we
abstracted or computed the observed and expected number of lung
cancer cases among NSAID users for each study and summed them
across studies to compute a summary meta-analytic relative risk
measure for users of aspirin and other NSAIDs with 95% CI
computed under Poisson assumptions for the numbers observed
among NSAID users.
RESULTS
The characteristics of the 573 lung cancer cases and the 857
sex- and age-matched controls are shown in Table 1; they
comprised more men (55%) than women. The average age at
diagnosis was 64 years. The cases comprised 26% adeno-, 24%
squamous cell, 22% small-cell and 10% non-small-cell carcinomas;
6% were of other specified histological types and 3% lacked
microscopic confirmation. Table 2 shows the relative risks for lung
cancer associated with smoking habits and occupational training.
Current smokers who had an estimated cumulative tobacco
consumption of 1–14, 15–29 and 30 or more pack-years had
highly significant 5-fold, 12-fold and 29-fold increased risks,
respectively, compared to study subjects who had never smoked.
After adjustment for smoking habits, skilled and unskilled workers
had significant 2.1- and 1.7-fold higher risks, respectively, than
those with higher education.
Use of acetaminophen at any time was associated with a modest
but significantly increased relative risk of 1.34 (95% CI, 1.07–1.68),
which, however, was reduced to a nonsignificantly increased risk
of 1.11 after adjustment for smoking habits and occupational
training (data not shown). Table 3 also shows that 362 (63%) of the
573 cases and 584 (68%) of the 857 controls had ever used NSAIDs;
NSAID use and lung cancer
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adjustment for age, sex, sub-study, smoking habits, length of
education and use of acetaminophen (OR, 0.86). There was no
clear variation in risk estimates for aspirin only, other NSAIDs
only or mixed use, although risk reduction with aspirin only was
slightly greater.
For self-reported use of all types of NSAIDs combined, we
observed little differences in relative risks for monthly vs weekly vs
daily use (Table 3). The adjusted relative risk for daily users was
0.77 (95% CI, 0.50–1.18). The trend analysis on the basis of all
NSAID prescriptions dispensed at pharmacies since 1995 showed a
reduced risk with increasing frequency of prescriptions. In the
fully adjusted model, study subjects who received the highest
number of prescriptions per year, that is at least four, had the
lowest risk estimate (OR, 0.49; 95% CI, 0.28–0.84) (Table 3)
composed of separate estimates of 0.43 (0.16–1.13) in the northern
Jutland case–control study and 0.53 (0.27–1.06) in the case–
control study nested in the prospective Diet, Cancer and Health
cohort study. For the combined study material, the decreasing
trend in risk with increasing number of annual prescriptions
reached statistical significance (Table 3). The protective effect of
heavily prescribed use of NSAIDs was more apparent for adeno-,
or 0.12 (95% CI 0.03–0.51) associated with at least four
prescriptions per year, than for squamous cell (RR 0.49; 95% CI
0.13–1.90) or small-cell and large-cell carcinomas combined (0.72;
0.17–2.98), although these estimates were based on small numbers
(data not shown).
Table 4 shows that trends of decreasing risk of lung cancer with
rising number of prescriptions were apparent for both aspirin and
other NSAIDs, being slightly stronger for the latter. As previously
indicated, the prescribed aspirin users were mainly users of low-
dose aspirin.
Table 5 summarises results from our meta-analysis of previous
investigations and shows that while case–control studies and trials
reported lower risks among NSAID users, there was much less
consistency among the 14 cohort studies. Across all studies, there
was heterogeneity of findings, with the relative risks ranging from
0.3 to 1.4. When reported data were weighted by the expected
numbers of lung cancers among NSAID users, the summary
relative risk among aspirin users was 0.99 (95% CI, 0.95–1.03;
P¼0.62); for non-aspirin (or unspecified) NSAIDs, it was 0.92
Table 1 Descriptive characteristics of 1430 study subjects in two case–control studies of lung cancer and use of NSAIDs
Northern Jutland
case–control study
Case–control study nested
in diet and cancer cohort study Combined study
Characteristic Cases % Controls % Cases % Controls % Cases % Controls %
Both sexes 144 100 428 100 429 100 429 100 573 100 857 100
Men 87 60 245 57 228 53 228 53 315 55 473 55
Women 57 40 183 43 201 47 201 47 258 45 384 45
Year of birth
o1930 25 17 69 16 6 1 0 0 31 5 69 8
1930–1944 89 62 250 58 407 95 413 96 496 87 663 77
X1945 30 21 109 26 16 4 16 4 46 8 125 15
Age at diagnosis
a (years)
o60 34 24 123 29 130 30 131 31 164 29 254 3
60–69 51 35 179 42 271 63 271 63 322 56 450 53
X70 59 41 126 29 28 7 27 6 87 15 153 18
Mean age (s.d.) (years) 67 (9) 65 (9) 63 (5) 63 (5) 64 (6) 64 (7)
Year of diagnosis
1994–96 0 0 — — 40 9 — — 40 7 — —
1997–99 0 0 — — 146 34 — — 146 25 — —
2000–02 0 0 — — 204 48 — — 204 36 — —
2003–05 144 100 — — 39 9 — — 183 32 — —
Year of interview (range) 2002–2005 1993–1997 1993–2005
aAge at diagnosis of lung cancer for cases and age at index date for controls.
Table 2 ORs for lung cancer by smoking habit and length of education,
with associated 95% CIs
Cases/controls
Lung cancer
Risk factor 573/857 OR
a 95% CI OR
b 95% CI
Smoking habit
Never 23/284 1 Reference — —
Former
410 years since
quitting
51/243 2.84 1.62–4.97 — —
p10 years since
quitting
52/58 16.0 8.22–31.1 — —
Current
1–14 pack-years 15/36 4.76 2.21–10.3 — —
15–29 pack-years 74/77 12.4 7.19–21.5 — —
X30 pack-years 353/149 28.9 17.8–47.1 — —
Age at start (years)
420 51/89 1 Reference 1 Reference
15–20 342/359 1.70 1.14–2.52 1.61 1.04–2.50
o15 157/124 2.82 1.74–4.56 2.53 1.45–4.41
Missing information 5/10
Occupational training
Master’s degree or
higher
73/137 1 Reference 1 Reference
Bachelor’s degree 149/250 1.27 0.87–1.85 1.10 0.69–1.76
Skilled worker 170/272 2.25 1.49–3.41 2.07 1.27–3.38
Unskilled worker 173/189 2.91 1.91–4.44 1.68 1.02–2.76
Missing information 8/9
CI¼confidence interval; OR, odds ratio.
aAdjusted for age, sex and study.
bAdjusted
for age, sex, study and smoking habit.
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NSAIDs, 0.95 (95% CI, 0.93–0.98; Po0.001). Adding our own
results to the meta-analysis results in slightly lower overall risk
estimates among NSAID users.
DISCUSSION
In this study of 573 patients with clinically and histologically
verified lung cancer and 857 population controls, we observed an
overall 14% non-statistically significant decrease in risk associated
with any use of aspirin and other NSAIDs after adjustment for
smoking habits, length of education and concomitant use of
acetaminophen. In an analysis according to self-reported
frequency of use, the risk reduction increased to 23%, although
still nonsignificant, among self-described daily users of NSAIDs.
Using objective pharmacy records, we observed a significant trend
of decreasing risk with increasing numbers of prescriptions, with a
50% reduction those among those with at least four NSAID
prescriptions per year 1–3 years before the index date.
Despite the relative consistency of experimental data on COX-2
tissue expression and lung cancer risk and the inhibiting potential
of NSAID treatment (Castonguay et al, 1998; Hosomi et al, 2000;
Thun et al, 2002), the overall epidemiological evidence for a
protective effect of NSAIDs on lung cancer is weak. Our meta-
analysis showed a significantly lowered risk, but only by 5%.
Several of the studies were limited by small sample size with
imprecise risk estimates, self-reported NSAID use, possibly biased
selection of controls and/or lack of information on smoking habits.
We addressed several of the above limitations. Its setting with a
national health service largely removed referral and diagnostic
biases. The availability of continuously updated information on
NSAID use from all pharmacies in Denmark, in addition to self-
reported information, helped us to minimise differential recall and
error in exposure assessment. This approach allowed establish-
ment of mutually exclusive exposure categories, including a
reference group of non-users of both prescription and OTC
NSAIDs. Recruitment of cases from highly specialised treatment
centres and the Danish Cancer Registry ensured accurate
ascertainment with minimal misclassification, and the availability
of detailed information on smoking habits, length of education and
use of acetaminophen reduced the risk for confounding.
Using self-reported information, use of NSAIDs was associated
with a modest, non-significant reduction in risk similar for the
three frequency categories. A comparison of self-reported use
and prescription records among participants in the Diet, Cancer and
Health cohort revealed that only 28% of individuals who reported
daily use of aspirin during the preceding year were so recorded
in the prescription database indicating frequent OTC purchases.
Conversely, of individuals filling two or more prescriptions for
aspirin within 1 year prior to enrolment, 98% reported its use in the
questionnaire at enrolment; the corresponding figures for non-
aspirin NSAIDs were 78 and 96%, indicating some misclassification
of self-reported data. The use of self-reported data vs prescription
based records may explain the somewhat different results of the risk
analyses. Although the self-reports ascertain OTC use not obtainable
in the prescription register, we tend to place more confidence in the
national database, where possible recall bias is eliminated.
A limitation is that duration of prescribed NSAID use is
unknown, as the nationwide prescription database was first started
Table 3 ORs for lung cancer and 95% CIs by pattern of use of NSAIDs
Cases/controls
Full study
Northern Jutland Diet and cancer cohort
Use of NSAIDS or acetaminophen 573/857 OR
a OR
b 95% CI OR
b OR
b
NSAIDs
Never
c 211/273 1 1 Reference 1 1
Any 362/584 0.92 0.86 0.65–1.14 0.78 0.91
Aspirin only 71/117 0.76 0.75 0.49–1.14 0.92 0.64
Other NSAIDs only 156/273 0.90 0.87 0.62–1.23 0.63 1.07
Mixed 135/194 1.09 0.94 0.65–1.35 0.98 0.97
Self-reported
Monthly 63/100 0.78 0.82 0.52–1.27 0.85 0.85
Weekly 47/64 0.82 0.79 0.46–1.34 1.16 0.79
Daily 86/161 1.12 0.77 0.50–1.18 0.73 0.84
Prescriptions/year
d
0.5–2 122/188 0.98 0.90 0.62–1.31 0.59 1.10
2–3 54/86 0.95 0.81 0.50–1.32 0.83 0.67
X4 33/79 0.66 0.49 0.28–0.84 0.43 0.53
Test for trend (P) 0.30 0.02 0.07 0.32
CI¼confidence interval; OR, odds ratio. Adjusted estimates are given for the combined study as well as for the Northern Jutland and Diet and Cancer cohort sub-studies.
aAdjusted for age, sex and study.
bAdjusted for age, sex, study, smoking habit, length of education and use of acetaminophen.
cNo self-reported use or prescriptions 41y e a r
before index date.
dExposure 1–3 years before index date.
Table 4 ORs for lung cancer and 95% CIs by prescribed use of aspirin
and other NSAIDs
Aspirin
b Other NSAIDs
Prescriptions/
year
a
Cases/
controls OR
c 95% CI
Cases/
controls OR
c 95% CI
Never 211/273 1 — 211/273 1 —
0.5–2 34/48 0.83 0.45–1.53 112/190 0.84 0.57–1.22
2–3 36/69 0.62 0.36–1.06 26/43 0.77 0.40–1.47
X4 14/22 0.74 0.32–1.71 13/36 0.41 0.18–0.93
Test for trend (P) 0.09 0.06
CI¼confidence interval; OR, odds ratio.
aExposure 1–3 years before index date.
bMainly low-dose aspirin for secondary prevention of cardiovascular disease.
cFully
adjusted model.
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a yearly number of prescriptions issued during a relatively recent
period might not be representative during the aetiologically
relevant periods. We had no data on compliance with the
prescriptions for NSAIDs, but the fact that the drugs were actually
dispensed at pharmacies and paid in part by the customers and
often refilled suggests that they were also consumed. Any non-
compliance would bias the risk estimates towards the null.
Our study, which overcomes some of the limitations that may
have hindered the detection of a beneficial effect of NSAIDs in
previous studies, provides some support for the hypothesis that
regular use of NSAIDs protects against lung cancer. The issue
remains uncertain, however, and more research using detailed data
on NSAID use and smoking is needed.
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